CLDN6 and neoplasm: The biodistribution results showed that [177Lu]Lu-DOTA-IMAB027 was targeted to the tumors of the TE-1-CLDN6 model and increased in tumor aggregation over time (Fig. 3C), with peak aggregation occurring at 96 h (27.1 ± 4.85 %ID/g).